乳腺癌TAC新辅助化疗与相关不良预后因素的关系分析  

Correlation of TAC neoadjuvant chemotherapy with poor prognosis factors of breast cancer

作　　者：庞钰文 相龙全 文益杨 PANG Yuwen;XIANG Longquan;WEN Yiyang(Department of Pathology,Jining No.1 People’s Hospital,Jining 272000,Shandong,China)

机构地区：[1]济宁市第一人民医院病理科,山东济宁272000

出　　处：《癌症进展》2022年第17期1762-1766,共5页Oncology Progress

基　　金：山东省医药卫生科技发展计划项目(2018WS473)。

摘　　要：目的探讨乳腺癌紫杉醇+环磷酰胺+吡柔比星(TAC)方案新辅助化疗与相关不良预后因素的关系。方法分析1561例乳腺癌患者(TAC新辅助化疗180例)同侧淋巴结转移、锁骨上淋巴结转移、残余脉管内肿瘤和肿瘤结节的发生情况。结果接受TAC新辅助化疗的乳腺癌患者同侧淋巴结转移率、锁骨上淋巴结转移率、残余脉管内肿瘤发生率和肿瘤结节发生率均高于直接手术患者(P﹤0.01)。轻度缓解和部分缓解患者同侧腋窝淋巴结转移率和残余脉管内肿瘤发生率均高于病理学完全缓解(pCR)患者,差异均有统计学意义(P﹤0.01)。结论TAC新辅助化疗可能提高乳腺癌同侧淋巴结转移率、锁骨上淋巴结转移率、残余脉管内肿瘤发生率和肿瘤结节发生率,尤其新辅助化疗效果不佳的患者,可能增加潜在复发与转移风险。Objective To investigate the correlation of taxol+cyclophosphamide+pirarubicin(TAC)neoadjuvant chemotherapy with poor prognosis factors of breast cancer.Method Axillary lymph nodal metastasis,supraclavicular lymph nodal metastasis,residual intravascular tumor and tumor deposits in 1561 cases of breast cancer(180 cases of TAC neoadjuvant chemotherapy)were analyzed.Result The incidence of axillary lymph nodal metastasis,supraclavicular lymph nodal metastasis,residual intravascular tumor and tumor deposits in patients with neoadjuvant chemotherapy were significantly higher than those in patients with direct surgery(P<0.01),and the incidence of axillary lymph nodal metastasis,residual intravascular tumor in patients with mild and partial response were higher than those in patients with pathological complete response(pCR)(P<0.01).Conclusion TAC neoadjuvant chemotherapy may promote the metastasis of breast cancer,including the incidence of axillary lymph nodal metastasis,supraclavicular lymph nodal metastasis,residual intravascular tumor and tumor deposits,especially in patients with ineffective neoadjuvant chemotherapy,which may increase the risk of potential recurrence and metastasis.

关 键 词：新辅助化疗 乳腺癌 TAC方案 预后因素 

分 类 号：R737.9[医药卫生—肿瘤]